The TLR4 agonist, monophosphoryl lipid A, attenuates the cytokine storm associated with respiratory syncytial virus vaccine-enhanced disease
The TLR4 agonist, monophosphoryl lipid A, attenuates the cytokine storm associated with respiratory syncytial virus vaccine-enhanced disease
复制标题
DOI：
10.1016/j.vaccine.2006.03.064
复制
发表时间：
2006-06-05
期刊：
影响因子：
5.5
通讯作者：
Blanco, Jorge C. G.
中科院分区：
文献类型：
--
作者：
Boukhvalova, Marina S.;Prince, Gregory A.;Blanco, Jorge C. G.
福尔马林灭活呼吸道合胞病毒疫苗(FI-RSV)诱导一种鲜为人知的免疫病理反应，导致接种者感染RSV后疾病加重。在棉鼠模型中，在FI-RSV配方中加入单磷酰脂A(MPL)被发现可以减轻与疫苗增强型疾病相关的肺部病理。在这里，我们报告MPL对FI-RSV疫苗增强型疾病的保护作用与Th1和Th2型细胞因子和趋化因子水平的显著降低有关，这些细胞因子和趋化因子通常是在RSV攻击时诱导的。我们的数据说明了FI-RSV疫苗接种和RSV感染引起的促炎反应的复杂性，以及MPL在改变这种反应中的潜在重要性。(C)2006爱思唯尔有限公司。保留所有权利。
Formalin-inactivated respiratory syncytial virus vaccine (FI-RSV) induces a poorly understood immunopathological response that leads to disease enhancement upon RSV infection of vaccinees. In the cotton rat model, inclusion of monophosphoryl lipid A (MPL) in the FI-RSV formulation was found to mitigate the lung pathology associated with vaccine-enhanced disease. Here we report that the protective effect of MPL on FI-RSV vaccine-enhanced disease is associated with a dramatic reduction in levels of Th1- and Th2-type cytokines and chemokines normally elicited in response to RSV challenge. Our data illustrate the complexity of proinflammatory response elicited by FI-RSV vaccination and RSV infection and the potential importance of MPL in modifying this response. (c) 2006 Elsevier Ltd. All rights reserved.